title: Tumor lysis syndrome following trastuzumab for breast cancer: a case report and review of the literature.
abstract: Tumor lysis syndrome, a complication of anticancer chemotherapy, results from rapid lysis of malignant cells. We report tumor lysis syndrome in a patient treated with trastuzumab for metastatic breast carcinoma. A 69-year-old woman was diagnosed with multiple liver metastases 1 month after mastectomy. As her liver functions had deteriorated, chemotherapeutic agents were contraindicated and she was treated with trastuzumab alone. On day 6 of the first course of trastuzumab, she developed tumor lysis syndrome. As her liver functions showed deterioration due to multiple hepatic metastases, hemodialysis was contraindicated. Acute renal failure worsened and she died 11 days after the administration of trastuzumab.
authors: Department of Breast Oncology, Juntendo University Hospital, 2-1-1 Hongo, Bunkyo-ku, Tokyo, 113-8421, Japan. fmuraka@juntendo.ac.jp.
authors: Fumi
authors: F
authors: Taira
authors: Department of Breast Oncology, Juntendo University Hospital, 2-1-1 Hongo, Bunkyo-ku, Tokyo, 113-8421, Japan.
authors: Yoshiya
authors: Y
authors: Horimoto
authors: Department of Breast Oncology, Juntendo University Hospital, 2-1-1 Hongo, Bunkyo-ku, Tokyo, 113-8421, Japan.
authors: Mitsue
authors: M
authors: Saito
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D005260:Female; D006801:Humans; D008113:Liver Neoplasms / Q000556:secondary; D000068878:Trastuzumab / Q000009:adverse effects*; D015275:Tumor Lysis Syndrome / Q000209:etiology*
chemical_list: D000970:Antineoplastic Agents; D000068878:Trastuzumab
keywords: Breast cancer; Molecular targeting drug; Solid tumor; Trastuzumab; Tumor lysis syndrome